Pfizer taps Cephalon exec to head US oncology

Share this article:
Pfizer named Elizabeth Barrett regional president, US for its Oncology Business Unit, a new position, with responsibility for Pfizer's US oncology sales, field operations and marketing.  

Barrett joins the company from Cephalon, where she was VP and general manager of the company's Oncology Business Unit. There, she launched the company into oncology in an integrated business unit, presiding over the marketing, sales and medical affairs organizations and developing the firm's strategy in the category.

Before joining Cephalon, she served as worldwide VP of sales and marketing for Veridex and VP of the critical care and surgery franchise at Ortho Biotech.

Barrett will report to Garry Nicholson, president and general manager, Oncology Business Unit.

Nicholson hailed her expertise in oncology and said: “As the Oncology Business Unit continues to explore and build upon new areas and tumor types, it is important that we have the right leaders in place to ensure that we can deliver superior total value not only internally within the company, but to the physicians and patients that we serve.”

Pfizer's oncology portfolio includes Sutent, for renal cell carcinoma and GIST, and Aromasin for breast cancer.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.